Connection

John Gnann to Humans

Back to Details
This is a "connection" page, showing publications John Gnann has written about Humans.
John Gnann
Connection Strength
0.369
Humans
  1. Lack of Efficacy of High-Titered Immunoglobulin in Patients with West Nile Virus Central Nervous System Disease. Emerg Infect Dis. 2019 11; 25(11):2064-2073.
    View in: PubMed
    Score: 0.026
  2. Genital Herpes. N Engl J Med. 2016 11 10; 375(19):1906.
    View in: PubMed
    Score: 0.021
  3. CLINICAL PRACTICE. Genital Herpes. N Engl J Med. 2016 Aug 18; 375(7):666-74.
    View in: PubMed
    Score: 0.021
  4. Impact of a rapid multiplex polymerase chain reaction blood culture identification technology on outcomes in patients with vancomycin-resistant Enterococcal bacteremia. Infect Dis (Lond). 2016 Oct; 48(10):732-7.
    View in: PubMed
    Score: 0.021
  5. Herpes Simplex Encephalitis: Lack of Clinical Benefit of Long-term Valacyclovir Therapy. Clin Infect Dis. 2015 Sep 01; 61(5):683-91.
    View in: PubMed
    Score: 0.019
  6. Reversible posterior leukoencephalopathy syndrome. Intern Emerg Med. 2014 Apr; 9(3):341-2.
    View in: PubMed
    Score: 0.017
  7. Kaposi's varicelliform eruption. Intern Emerg Med. 2014 Feb; 9(1):101-2.
    View in: PubMed
    Score: 0.017
  8. Mosquito bites and eastern equine encephalitis. QJM. 2014 May; 107(5):397-8.
    View in: PubMed
    Score: 0.017
  9. Varicella-zoster virus: Prevention through vaccination. Clin Obstet Gynecol. 2012 Jun; 55(2):560-70.
    View in: PubMed
    Score: 0.016
  10. Herpes zoster in the age of focused immunosuppressive therapy. JAMA. 2009 Feb 18; 301(7):774-5.
    View in: PubMed
    Score: 0.013
  11. Vaccination to prevent herpes zoster in older adults. J Pain. 2008 Jan; 9(1 Suppl 1):S31-6.
    View in: PubMed
    Score: 0.012
  12. The incidence and severity of herpes simplex encephalitis in Sweden, 1990-2001. Clin Infect Dis. 2007 Oct 01; 45(7):881-2.
    View in: PubMed
    Score: 0.011
  13. A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level. Clin Infect Dis. 2003 Jan 15; 36(2):207-11.
    View in: PubMed
    Score: 0.008
  14. Clinical practice. Herpes zoster. N Engl J Med. 2002 Aug 01; 347(5):340-6.
    View in: PubMed
    Score: 0.008
  15. Viral encephalitis: familiar infections and emerging pathogens. Lancet. 2002 Feb 09; 359(9305):507-13.
    View in: PubMed
    Score: 0.008
  16. Risk factors for mortality and progression to severe COVID-19 disease in the Southeast region in the United States: A report from the SEUS Study Group. Infect Control Hosp Epidemiol. 2021 12; 42(12):1464-1472.
    View in: PubMed
    Score: 0.007
  17. Human herpesvirus 8 and Kaposi's sarcoma in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000 Apr; 30 Suppl 1:S72-6.
    View in: PubMed
    Score: 0.007
  18. Herpes zoster: focus on treatment in older adults. Antiviral Res. 1999 Dec 31; 44(3):145-54.
    View in: PubMed
    Score: 0.007
  19. Herpes zoster: risk categories for persistent pain. J Infect Dis. 1999 Jan; 179(1):9-15.
    View in: PubMed
    Score: 0.006
  20. Therapeutic approaches to the management of herpes zoster. Adv Exp Med Biol. 1999; 458:159-65.
    View in: PubMed
    Score: 0.006
  21. Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group. Antimicrob Agents Chemother. 1998 May; 42(5):1139-45.
    View in: PubMed
    Score: 0.006
  22. Histoplasma meets Crohn's disease: a rare case of new-onset ascites. BMJ Case Rep. 2018 Apr 17; 2018.
    View in: PubMed
    Score: 0.006
  23. Herpes zoster in patients with human immunodeficiency virus infection--an ever-expanding spectrum of disease. Clin Infect Dis. 1995 Oct; 21(4):989-90.
    View in: PubMed
    Score: 0.005
  24. West Nile virus neuroinvasive disease: neurological manifestations and prospective longitudinal outcomes. BMC Infect Dis. 2014 May 09; 14:248.
    View in: PubMed
    Score: 0.005
  25. New antivirals with activity against varicella-zoster virus. Ann Neurol. 1994; 35 Suppl:S69-72.
    View in: PubMed
    Score: 0.004
  26. Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. J Infect Dis. 2013 Nov 01; 208(9):1386-90.
    View in: PubMed
    Score: 0.004
  27. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013 Aug 15; 208(4):559-63.
    View in: PubMed
    Score: 0.004
  28. Acyclovir: a decade later. N Engl J Med. 1992 Sep 10; 327(11):782-9.
    View in: PubMed
    Score: 0.004
  29. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012 Apr; 54(7):922-8.
    View in: PubMed
    Score: 0.004
  30. Natural history and treatment of varicella-zoster in high-risk populations. J Hosp Infect. 1991 Jun; 18 Suppl A:317-29.
    View in: PubMed
    Score: 0.004
  31. Acyclovir: the past ten years. Adv Exp Med Biol. 1990; 278:243-53.
    View in: PubMed
    Score: 0.003
  32. Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. Clin Infect Dis. 2009 Sep 15; 49(6):924-7.
    View in: PubMed
    Score: 0.003
  33. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain. 2009 Apr; 142(3):209-217.
    View in: PubMed
    Score: 0.003
  34. Custom-designed synthetic peptide immunoassays for distinguishing HIV type 1 and type 2 infections. Methods Enzymol. 1989; 178:693-714.
    View in: PubMed
    Score: 0.003
  35. Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial. J Clin Virol. 2008 Oct; 43(2):190-5.
    View in: PubMed
    Score: 0.003
  36. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis. 2008 Mar 01; 197 Suppl 2:S207-15.
    View in: PubMed
    Score: 0.003
  37. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain. 2008 Jan; 9(1 Suppl 1):S37-44.
    View in: PubMed
    Score: 0.003
  38. Synthetic peptide immunoassay distinguishes HIV type 1 and HIV type 2 infections. Science. 1987 Sep 11; 237(4820):1346-9.
    View in: PubMed
    Score: 0.003
  39. Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus. J Infect Dis. 1987 Aug; 156(2):261-7.
    View in: PubMed
    Score: 0.003
  40. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007 Jan 01; 44 Suppl 1:S1-26.
    View in: PubMed
    Score: 0.003
  41. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2007 Jan 15; 44(2):245-9.
    View in: PubMed
    Score: 0.003
  42. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl. 2005 Aug; 11(8):941-9.
    View in: PubMed
    Score: 0.002
  43. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 02; 352(22):2271-84.
    View in: PubMed
    Score: 0.002
  44. A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Res. 2004 Nov; 64(2):103-11.
    View in: PubMed
    Score: 0.002
  45. Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications. Pharmacotherapy. 1983 Sep-Oct; 3(5):275-83.
    View in: PubMed
    Score: 0.002
  46. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther. 2003 Jun; 8(3):183-90.
    View in: PubMed
    Score: 0.002
  47. Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report. Ann Intern Med. 2000 Sep 19; 133(6):435-8.
    View in: PubMed
    Score: 0.002
  48. A mixed model for factors predictive of pain in AIDS patients with herpes zoster. J Pain Symptom Manage. 1999 Jun; 17(6):410-7.
    View in: PubMed
    Score: 0.002
  49. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med. 1996 Sep 01; 125(5):376-83.
    View in: PubMed
    Score: 0.001
  50. Unique clinical trial design: combination acyclovir plus prednisone therapy of localized zoster in the normal host. Antiviral Res. 1996 Jan; 29(1):67-8.
    View in: PubMed
    Score: 0.001
  51. Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group. J Infect Dis. 1992 Mar; 165(3):450-5.
    View in: PubMed
    Score: 0.001
  52. Therapy for women hospitalized with acute pyelonephritis: a randomized trial of ampicillin versus trimethoprim-sulfamethoxazole for 14 days. J Infect Dis. 1991 Feb; 163(2):325-30.
    View in: PubMed
    Score: 0.001
  53. T cell recognition of HIV synthetic peptides in a natural infection. J Immunol. 1989 Feb 15; 142(4):1166-76.
    View in: PubMed
    Score: 0.001
  54. Intravenous acyclovir therapy of first episodes of genital herpes: a multicenter double-blind, placebo-controlled trial. Am J Med. 1988 Sep; 85(3):301-6.
    View in: PubMed
    Score: 0.001
  55. Acute glomerulonephritis following group G streptococcal infection. J Infect Dis. 1987 Aug; 156(2):411-2.
    View in: PubMed
    Score: 0.001
  56. A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo. J Infect Dis. 1984 Jul; 150(1):1-6.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.